Genetic code expansion (GCE) technology enables the site-specific incorporation of non-canonical amino acids (ncAAs) into proteins, vastly expanding their chemical and functional properties. Leveraging a proprietary GCEngine platform for orthogonal aaRS/tRNA pair development, our company pioneers the application of GCE for vaccine innovation. Our ncAA incorporated epitope optimization service provides a powerful strategy to enhance vaccine immunogenicity, stability, and specificity by strategically introducing unique biochemical handles into antigenic epitopes, enabling precise chemical modifications and unlocking novel mechanisms of immune activation.
This ncAA incorporated epitope optimization for vaccine involves the rational design and genetic engineering of vaccine immunogens (e.g., viral proteins, tumor-associated antigens) to contain one or more site-specifically incorporated ncAAs. These ncAAs serve as bioorthogonal chemical handles within key epitope regions. This allows for subsequent, precise conjugation of various payloads, such as immunostimulatory molecules, carrier proteins, fluorescent probes, or degraders, directly to the antigen itself. The process facilitates the modulation of epitope presentation, enhancement of immune recognition, redirection of immune responses, and tracking of antigen fate in vivo, moving beyond the limitations of traditional genetic fusion or random chemical conjugation methods.
Augmenting Immunogenicity of Epitopes
Introducing ncAAs into conserved yet weakly immunogenic viral or bacterial epitopes (e.g., HIV or influenza) enables the site-specific conjugation of immunostimulatory molecules (e.g., TLR agonists) to locally enhance immune activation.
Engineering Precision Cancer Vaccines
Incorporating ncAAs into tumor-specific antigens or neoantigens allows for the directed attachment of T-cell adjuvants, targeting moieties, or molecules designed to improve antigen cross-presentation, aiming to potentiate cellular immune responses.
Enabling Modular Vaccine Platforms
Creating antigen scaffolds containing ncAA "landing sites" facilitates a "plug-and-play" approach for the oriented conjugation of diverse epitopes or adjuvants, potentially accelerating the development of multivalent or multi-functional vaccines.
Elucidating Immune Mechanisms
Utilizing ncAA-incorporated antigens bearing cleavable linkers or tracking probes (e.g., fluorophores, affinity tags) provides powerful tools for dissecting antigen processing, presentation pathways, and B/T cell engagement kinetics.
Built on a foundation of high-throughput screening and directed evolution, the core platform rapidly identifies and optimizes orthogonal aaRS/tRNA pairs for a broad range of ncAAs. This capability ensures efficient and faithful ncAA incorporation across diverse expression systems, including E. coli, yeast, mammalian cells (e.g., CHO, HEK293), and cell-free systems. The integrated workflow spans from orthogonal pair discovery to in vitro validation and in vivo application, offering a seamless transition from concept to characterized candidate.
Our service can be tailored to various strategic approaches for vaccine enhancement through ncAA incorporation.
Adjuvant Direct Conjugation
Site-specific coupling of TLR agonists, cytokines, or other immunostimulants directly to the epitope to locally enhance immune activation.
Carrier Protein Site-Specific Coupling
Controlled, oriented conjugation of weak antigenic peptides or epitopes to a carrier protein (e.g., KLH) to improve immunogenicity without carrier-induced epitope suppression.
Epitope Stability Modulation
Incorporation of ncAAs that promote cross-linking or introduce stabilizing interactions within the epitope to maintain a desired, immunogenic conformation.
Biosensor Integration
Incorporation of ncAAs for attaching fluorescent or biotin tags to track antigen uptake, processing, and presentation in vitro or ex vivo.
By combining a cutting-edge GCEngine platform with focused vaccine application expertise, we provide a unique and precise service for next-generation epitope optimization. Our approach enables control over antigen modification, opening avenues for more potent, specific, and rationally designed vaccines. For detailed project consultations and to explore how ncAA incorporation can advance your vaccine program, please contact our scientific team.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.